Poster Presentation Clinical Oncology Society of Australia Annual Scientific Meeting 2026

Patient characteristics and treatment patterns of patients with advanced NSCLC harboring MET exon 14 (METex14) skipping enrolled in MOMENT disease registry (143312)

Stephanie Gasking 1 , Michael Thomas 2 , Petros Christopoulos 3 , Maximilian Hochmair 4 , Jonas Kuon 5 , Paul Wheatley-Price 6 , Geoffrey Liu 7 , Vincent Fallet 8 , Nicolas Girard 9 , Sanjay Popat 10 , Nir Peled 11 , Gabriele Minuti 12 , Giuseppe Lo Russo 13 , Egbert Smit 14 , Andrea Lopes Machado 15 , Martin Reck 16 , Steven Ting 17 , Andreas Johne 18 , Emmanuelle Boutmy 19 , Marie-Noelle Solbes 20 , Seyed Hamidreza Mahmoudpour 21
  1. Merck Healthcare Pty. Ltd., Macquarie Park, Australia, an affiliate of Merck KGaA, Australia
  2. Department of Thoracic Oncology, Thoraxklinik, Heidelberg University Hospital and National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and Heidelberg University Hospital, Heidelberg, Germany, Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), Heidelberg, Germany
  3. Department of Thoracic Oncology, Thoraxklinik, Heidelberg University Hospital and National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and Heidelberg University Hospital, Heidelberg, Germany, Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), Heidelberg, Germany
  4. Department of Respiratory & Critical Care Medicine, Karl Landsteiner Institute of Lung Research & Pulmonary Oncology, Klinik Floridsdorf, Vienna, Austria
  5. Department of Thoracic Oncology, Thoraxklinik at Heidelberg University Hospital, Translational Lung Research Center Heidelberg TLRC-H, Member of the German Center for Lung Research DZL, Heidelberg, Germany
  6. University of Ottawa / Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
  7. Princess Margaret Cancer Centre, Toronto, Ontario, Canada
  8. Department of Pneumology and Thoracic Oncology, Tenon Hospital, Assistance Publique Hôpitaux de Paris and GRC 4, Theranoscan, Sorbonne Université, Paris, France
  9. Institut Curie - Hôpital de Paris, Paris, France
  10. The Royal Marsden Hospital, London, UK
  11. Helmesely Cancer Center, Shaare Zedek Medical Center, Jerusalem, Israel
  12. National Cancer Institute, IRCCS, Regina Elena, via Elio Chianesi 5300144, Rome, Italy
  13. Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
  14. Department of Pulmonary Diseases, Leiden University Medical Centre, Leiden, The Netherlands
  15. Department of Pulmonary Oncology - ULS de Santa Maria, Hospital Pulido Valente, Lisbon, Portugal
  16. Department of Thoracic Oncology, Airway Research Center North, German Center for Lung Research, LungenClinic, Grosshansdorf, Germany
  17. Cytel, Singapore
  18. Global Clinical Development, Merck Healthcare KGaA, Darmstadt, Germany
  19. Patient Focused Real World Evidence (PRWE), Merck Healthcare KGaA, Darmstadt, Germany
  20. Oncology Medical Unit, Merck Serono S.A.S., Lyon, France, an affiliate of Merck KGaA
  21. Patient Focused Real World Evidence (PRWE), Merck Healthcare KGaA, Darmstadt, Germany

Aims: METex14 skipping occurs in 3–4% of NSCLC cases, and real-world data in patients receiving conventional therapies are limited. The MOMENT registry (NCT05376891) prospectively collects data from patients with advanced NSCLC harboring METex14 skipping treated in routine clinical practice. This registry is ongoing and continuously collects further data. Here, we provide an overview based on approximately 50% enrolment.

Methods: The MOMENT registry is currently active at >60 sites in 14 countries and will enroll ~700 patients with advanced NSCLC and confirmed METex14 skipping receiving systemic treatment. Collected data include biomarker testing results, demographics, baseline clinical characteristics, and treatment details.

Results: At about 50% enrollment (data cut-off: Oct 2025), 360 patients had been enrolled (start date: Oct 2022). Median age was 75 years; 54.2% were female, 39.4% never smoked, 46.1% had ECOG PS of 1, 64.7% had positive PD-L1 status, and 78.3% were enrolled in Europe. Most common baseline distant metastatic sites were bone (44.6%), brain (22.6%), and contralateral lung (16.0%). Most reported comorbidity category was vascular disorders (8.9%). TKI monotherapy was the most common systemic treatment with 36.3% of patients in 1L (n=122), 59.1% in 2L (n=94), and 37.5% in 3L (n=18). Among TKI monotherapy in 1L, 56.6% patients received tepotinib and 24.6% received capmatinib; in 2L, 62.8% and 24.5% received tepotinib and capmatinib, respectively. Other TKIs included bozitinib, cabozantinib, crizotinib, erlotinib, gefitinib, osimertinib, and vebreltinib. Similarly, other treatment types were immunotherapy-chemotherapy combination, immunotherapy only, chemotherapy only, others/unknown and TKI combination.

Conclusions: This interim descriptive analysis highlights progress in the MOMENT registry, yielding a growing dataset with improving quality. The analysis showed integration of targeted treatment into routine clinical practice either in treatment-naïve or previously treated patients with advanced NSCLC harboring METex14 skipping. These data are from an ongoing registry and may be incomplete or subject to change.